Study Details

Back to Search Results

Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.

N/A

Astellas Study ID

The unique identification code given by the study sponsor.

ESN364-HF-204

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2015-002578-20

Condition

Hot Flashes

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

40 Years - 65 Years

Sex

Female

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Sep 2015 - Oct 2016

Masking

Double (Participant, Investigator)

Enrollment number

87

Pilot/Phase IIa Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site BE32001

Gent, Belgium, 9000

Site BE32003

Genk, Belgium, 3600

Site BE32004

Brussels, Belgium, 1000

Site BE32005

Kraainem, Belgium, 1950

Site BE32006

Jette, Belgium, 1090

Site BE32007

Leuven, Belgium

Site BE32008

Mons, Belgium, 7000

Site BE32009

Tienen, Belgium, 3300

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo